Overview

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib